ArticleFrontiers in immunology2025
METTL3 inhibition alleviates neuroinflammation and apoptosis by reducing ETV4 m6A modification.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ETV4 Improves Cerebral Ischemia-Reperfusion Injury by Restraining YBX1-GPX4-Ferroptosis Cascades.Brain and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) triggers devastating secondary brain injury driven by maladaptive microglial activation and neuroinflammation. While N6-methyladenosine (m6A) RNA methylation influences inflammation, its spatiotemporal regulation in ICH microglia remains unclear. Here, we identified METTL3 as a key epigenetic driver that promotes neuropathology post-ICH. Our analyses revealed that upregulated METTL3 expression in activated microglia in ICH model mice was correlated with increased global m6A levels. Functional studies have demonstrated that METTL3 depletion attenuates the release of proinflammatory cytokines (TNF-α, IL-1β, and IL-6), suppresses NF-κB activation, and reduces apoptosis in microglia. Mechanistically, MeRIP-seq and RNA-seq identified the transcription factor ETV4 as a METTL3 target, where METTL3-mediated m6A modification of the ETV4 3'-UTR recruits the reader IGF2BP2 to increase mRNA stability. This axis drives NF-κB-mediated inflammation and caspase-3-dependent apoptosis. Overall, our work reveals the role of METTL3 in sustaining neuroinflammation and inducing apoptosis via m6A/ETV4 stabilization and suggests that METTL3 inhibition is a promising strategy for ameliorating ICH injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.